IBIO

Quote

Short

News

Articles

Message Board

iBio Inc. (NASDAQ : IBIO ) News

iBio Inc. (NASDAQ: IBIO) News Releases

IBIO News Releases

June 02, 2026 04:01:00 pm

GlobeNewswire

iBio to Participate in Upcoming Healthcare Investor Conferences

June 02, 2026 07:00:00 am

GlobeNewswire

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

May 26, 2026 03:56:18 am

SeekingAlpha

Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit

May 12, 2026 04:11:21 pm

SeekingAlpha

iBio GAAP EPS of -$0.07 misses by $0.01

May 12, 2026 04:05:00 pm

GlobeNewswire

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 08, 2026 07:15:00 am

GlobeNewswire

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

April 08, 2026 07:00:00 am

GlobeNewswire

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

March 17, 2026 11:02:20 pm

SeekingAlpha

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

March 16, 2026 04:30:00 pm

GlobeNewswire

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

March 09, 2026 07:00:00 am

GlobeNewswire

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account